Chemotherapy-Free Intervals in Management of Metastatic Colorectal Cancer

Axel Grothey, MD, discusses factors that influence treatment selection in patients with mCRC.

Axel Grothey, MD, and John Marshall, MD, discuss first-line treatment options in patients with metastatic colorectal cancer.

Axel Grothey, MD, and John Marshall, MD, discuss strategies for optimizing first-line treatment in metastatic colorectal cancer and the role of adjuvant therapy.

Experts in metastatic colorectal cancer discuss when and in which patients to use a chemotherapy-free treatment interval.

Experts in metastatic colorectal cancer review therapeutic options after progression for patients with mCRC.

John Marshall, MD, reviews efficacy data from the ReDOS study of regorafenib in patients with mCRC.

Axel Grothey, MD, and John Marshall, MD, discuss safety results from the ReDOS study of regorafenib in patients with mCRC.

Experts in mCRC review data on TAS-102 and discuss how best to sequence therapies in the third or fourth line.

John Marshall, MD, and Axel Grothey, MD, discuss how molecular testing results guide treatment decisions in patients with mCRC.

Experts in CRC discuss questions and management of mCRC.